Protective Effect of HMG-CoA Reductase Inhibitor Rosuvastatin on Doxorubicin-Induced Cognitive Impairment, Oxidative Stress and Neuroinflammation: Possible Role of CREB, ERK1/2, and BDNF
Özet
During or after chemotherapy, cognitive impairments characterized by forgetfulness, difficulty concentrating, and depressive and anxiety-like symptoms are observed. There is limited research examining the effects of rosuvastatin (RVS), an HMG-CoA reductase inhibitor, in the context of neuroinflammation-related cognitive disruption. Here, we aimed to investigate the neuroprotective potential of RVS against doxorubicin (DOX)-induced cognitive impairments. Experimental groups were planned as control (normal saline, intraperitoneal), DOX (total cumulative dose 10 mg/kg, intraperitoneal), RVS (10 mg/kg, oral, 20 days), and RVS + DOX. Efficacy was monitored by applying a battery of behavioral assessments, as well as biochemical, genetic, histopathological, and immunohistochemical examinations. Results from Morris water maze (MWM), passive avoidance, locomotion activity, and elevated plus maze (EPM) tests showed that DOX administration caused behavioral disorders. Moreover, DOX increased the levels of inducible nitric oxide synthase (iNOS), malondialdehyde (MDA), and tumor necrosis factor-α (TNF-α), while decreasing the levels of interleukin-10 (IL-10), glutathione (GSH), superoxide dismutase, catalase (SOD), endothelial nitric oxide (eNOS), and catalase (CAT). Co-treatment with RSV significantly attenuated DOX-induced behavioral changes and oxidative stress markers. In addition, similar to the immunohistochemical results, we determined that it increased the expression levels of extracellular signal-related kinases 1/2 (ERK1/2), cyclic adenosine monophosphate response element binding protein (CREB), and brain-derived neurotrophic factor (BDNF) and restored the histopathological structure of the brain. Therefore, these results indicated that RSV has a neuroprotective effect against DOX-induced cognitive impairment by reducing neurobehavioral impairments, exerting antioxidant and anti-inflammatory effects, and modulating brain growth factors. © The Author(s) 2025.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Yeni, Yesim | |
| dc.contributor.author | Cicek, Betul | |
| dc.contributor.author | Hacimuftuoglu, Ahmet | |
| dc.contributor.author | Ozkaraca, Mustafa | |
| dc.contributor.author | Lacin, Burak Batuhan | |
| dc.date.accessioned | 2026-10-18T20:25:59.605411553Z | |
| dc.date.available | 2026-10-18T20:25:59.605411553Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | During or after chemotherapy, cognitive impairments characterized by forgetfulness, difficulty concentrating, and depressive and anxiety-like symptoms are observed. There is limited research examining the effects of rosuvastatin (RVS), an HMG-CoA reductase inhibitor, in the context of neuroinflammation-related cognitive disruption. Here, we aimed to investigate the neuroprotective potential of RVS against doxorubicin (DOX)-induced cognitive impairments. Experimental groups were planned as control (normal saline, intraperitoneal), DOX (total cumulative dose 10 mg/kg, intraperitoneal), RVS (10 mg/kg, oral, 20 days), and RVS + DOX. Efficacy was monitored by applying a battery of behavioral assessments, as well as biochemical, genetic, histopathological, and immunohistochemical examinations. Results from Morris water maze (MWM), passive avoidance, locomotion activity, and elevated plus maze (EPM) tests showed that DOX administration caused behavioral disorders. Moreover, DOX increased the levels of inducible nitric oxide synthase (iNOS), malondialdehyde (MDA), and tumor necrosis factor-α (TNF-α), while decreasing the levels of interleukin-10 (IL-10), glutathione (GSH), superoxide dismutase, catalase (SOD), endothelial nitric oxide (eNOS), and catalase (CAT). Co-treatment with RSV significantly attenuated DOX-induced behavioral changes and oxidative stress markers. In addition, similar to the immunohistochemical results, we determined that it increased the expression levels of extracellular signal-related kinases 1/2 (ERK1/2), cyclic adenosine monophosphate response element binding protein (CREB), and brain-derived neurotrophic factor (BDNF) and restored the histopathological structure of the brain. Therefore, these results indicated that RSV has a neuroprotective effect against DOX-induced cognitive impairment by reducing neurobehavioral impairments, exerting antioxidant and anti-inflammatory effects, and modulating brain growth factors. © The Author(s) 2025. | |
| dc.description.sponsorship | Open access funding provided by the Scientific and Technological Research Council of T\u00FCrkiye (T\u00DCB\u0130TAK). | |
| dc.identifier.doi | 10.1007/s11481-025-10213-6 | |
| dc.identifier.eissn | 1557-1904 | |
| dc.identifier.issn | 1557-1890 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmcid | PMC12075306 | |
| dc.identifier.pmid | 40358798 | |
| dc.identifier.scopus | 2-s2.0-105004909377 | |
| dc.identifier.startpage | 53 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10873 | |
| dc.identifier.volume | 20 | |
| dc.identifier.wos | WOS:001487356200001 | |
| dc.language.iso | en | |
| dc.publisher | Springer | |
| dc.relation.ispartof | Journal of Neuroimmune Pharmacology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Cognitive impairment | |
| dc.subject | Doxorubicin | |
| dc.subject | Neuroinflammation | |
| dc.subject | Neuroplasticity | |
| dc.subject | Rosuvastatin | |
| dc.subject | Animals | |
| dc.subject | Antibiotics, Antineoplastic | |
| dc.subject | Brain-Derived Neurotrophic Factor | |
| dc.subject | Cognitive Dysfunction | |
| dc.subject | Cyclic AMP Response Element-Binding Protein | |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors | |
| dc.subject | Male | |
| dc.subject | MAP Kinase Signaling System | |
| dc.subject | Neuroinflammatory Diseases | |
| dc.subject | Neuroprotective Agents | |
| dc.subject | Oxidative Stress | |
| dc.subject | Rats | |
| dc.subject | Rats, Wistar | |
| dc.subject | Rosuvastatin Calcium | |
| dc.subject | amyloid beta protein | |
| dc.subject | antioxidant | |
| dc.subject | brain derived neurotrophic factor | |
| dc.subject | catalase | |
| dc.subject | cyclic AMP responsive element binding protein | |
| dc.subject | interleukin 10 | |
| dc.subject | ketamine | |
| dc.subject | malonaldehyde | |
| dc.subject | mitogen activated protein kinase | |
| dc.subject | nitric oxide | |
| dc.subject | superoxide dismutase | |
| dc.title | Protective Effect of HMG-CoA Reductase Inhibitor Rosuvastatin on Doxorubicin-Induced Cognitive Impairment, Oxidative Stress and Neuroinflammation: Possible Role of CREB, ERK1/2, and BDNF | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 11 | |
| rdl.citation.wos | 10 | |
| rdl.department | Faculty of Medicine, Department of Physiology, Erzincan Binali Yildirim University, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
